IP Library Granted Patent US 11,304,920
Granted Patent B2
US 11,304,920 · App. 17/056,290 · Granted Apr 19, 2022

Compositions for improving sexual function

Inventors: Djamaluddin Zaferan (Copenhagen, DK); Jahangir Khan (Copenhagen, DK)
Assignee: INXO A/S
A61K31/198A61K31/352A61P15/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,304,920
App. No.
17/056,290
Granted
Apr 19, 2022
Kind
B2
Abstract

The present invention relates to compositions comprising L-arginine and L-citrulline in specific ratios. In particular, the present invention relates to the use of such compositions for improving sexual function in a healthy human subject.

Claims (10)

1. Method of improving sexual function of a sexually healthy human subject on demand, comprising:

administering a composition or unit dosage comprising L-arginine and L-citrulline or a physiologically acceptable salt or hydrate of any one thereof, wherein the content of L-arginine or a physiologically acceptable salt or hydrate thereof is at least 4.0 g and the content of L-citrulline or a physiologically acceptable salt or hydrate thereof is at least 1.0 g, wherein sexual function is improved for a time period of up to 6 hours.

2. The method according to claim 1 for improving sexual arousal in a sexually healthy human subject.

3. The method according to claim 1 , wherein the human subject is a female.

4. The method according to claim 3 , for improving orgasmic function in a sexually healthy female subject.

5. The method according to claim 1 , wherein the human subject is a male.

6. The method according to claim 5 , for improving IELT in a sexually healthy male subject.

7. The method according to claim 1 , wherein the composition or unit dose is administered 0.5-5.5 hours prior to sexual activity.

8. The method according to claim 1 , wherein the amount of L-arginine or a physiologically acceptable salt or hydrate thereof is 4.0-20.0 g, and wherein the content of L-citrulline or a physiologically acceptable salt or hydrate thereof is 1.0-3.0 g.

9. The method according to claim 1 , wherein the unit dosage comprises L-arginine and L-citrulline or physiologically acceptable salts or hydrates thereof in a combined amount in the range of from 6-14 g.

Assignments (3)
CHANGE OF NAME Recorded Feb 3, 2021
From: INXO IVS
To: INXO APS
Reel/Frame 055210/0144 →
CHANGE OF NAME Recorded Feb 3, 2021
From: INXO APS
To: INXO A/S
Reel/Frame 055210/0155 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 17, 2020
From: ZAFERAN, DJAMALUDDIN; KHAN, JAHANGIR
To: INXO IVS
Reel/Frame 054452/0376 →
Priority Claims (1)
DK PA 2018 70801 · Dec 7, 2018 · national
Continuity (2)
Continuation In Part 16706087 · Dec 6, 2019
Related Publication 20210353576A1 · Nov 18, 2021